financetom
Business
financetom
/
Business
/
Gentex's Q3 Performance Defies Auto Industry Headwinds, Trims 2024 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Gentex's Q3 Performance Defies Auto Industry Headwinds, Trims 2024 Outlook
Oct 27, 2024 11:11 PM

Fire protection company Gentex Corporation ( GNTX ) shares are trading higher after the company reported third-quarter earnings per share of 53 cents, beating the street view of 49 cents.

Quarterly revenues of $608.53 million, beating the analyst consensus of $592.14 million.

For the third quarter, the gross margin was 33.5% versus 33.2% a year ago due to the higher revenue levels and purchasing cost reductions.

Operating income was reported at $125.7 million, while net income totaled $122.5 million, marking a 17% increase year over year.

Global light vehicle production declined by 5% in the third quarter compared to the third quarter of 2023.

Also Read: What’s Going On With Spirit Airlines Stock Friday

“During the third quarter of 2024, light vehicle production weakened across all major regions, but especially in our primary markets,” said Gentex ( GNTX ) President and CEO Steve Downing.

“The production declines resulted in a sales shortfall of approximately $25 – $30 million for the quarter, but despite that weakness in our end markets, we were able to outperform our primary markets by 12%.”

Outlook: Gentex ( GNTX ) has revised its fiscal year 2024 outlook, now expecting net sales to be between $2.35 billion and $2.40 billion ($2.386 billion estimate), compared to the previous guidance of $2.40 billion to $2.50 billion.

The company also projects a gross margin of 33.5% to 34.0%, down from the prior forecast of 34% to 34.5%.

Gentex ( GNTX ) is updating calendar year 2025 revenue estimates to approximately $2.45 billion – $2.55 billion (prior view: $2.6 billion – $2.7 billion).

Price Action: GNTX shares are trading higher by 4.89% to $31.11 at last check Friday.

Read Next:

Colgate-Palmolive Beats Q3 Earnings Amid Market Share Gains And Margin Expansion, Raises 2024 Outlook

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Specialty retailer Zumiez beats Q2 revenue expectations
Specialty retailer Zumiez beats Q2 revenue expectations
Sep 4, 2025
Overview * Zumiez ( ZUMZ ) fiscal Q2 revenue rises 1.9%, beating analysts' expectations, per LSEG data * Comparable sales for fiscal Q2 up 2.5% year-over-year * Company posted a net loss of $1.0 mln, or $0.06 per share Outlook * Zumiez ( ZUMZ ) projects Q3 net sales between $232 mln and $237 mln * Company expects Q3 comparable...
Argan Fiscal Q2 Earnings, Revenue Rise
Argan Fiscal Q2 Earnings, Revenue Rise
Sep 4, 2025
04:21 PM EDT, 09/04/2025 (MT Newswires) -- Argan (AGX) reported fiscal Q2 earnings late Thursday of $2.50 per diluted share, up from $1.31 a year earlier. Two analysts polled by FactSet expected $1.74. Revenue for the quarter ended July 31 was $237.7 million, up from $227.0 million a year earlier. Three analysts surveyed by FactSet expected $243.9 million. Shares fell...
Agentic automation company UiPath beats Q2 revenue estimates
Agentic automation company UiPath beats Q2 revenue estimates
Sep 4, 2025
Overview * UiPath fiscal Q2 2026 revenue rises 14% yr/yr, beating analysts' expectations * Adjusted operating income for fiscal Q2 beats estimates, reaching $62 mln * Company's ARR grows 11% yr/yr to $1.723 bln Outlook * UiPath ( PATH ) expects Q3 fiscal 2026 revenue of $390 mln to $395 mln * Company forecasts Q3 fiscal 2026 ARR of $1.771...
Dexcom Insider Sold Shares Worth $357,796, According to a Recent SEC Filing
Dexcom Insider Sold Shares Worth $357,796, According to a Recent SEC Filing
Sep 4, 2025
04:19 PM EDT, 09/04/2025 (MT Newswires) -- Jereme M Sylvain, Executive Vice President, Chief Financial Officer, on September 02, 2025, sold 4,824 shares in Dexcom ( DXCM ) for $357,796. Following the Form 4 filing with the SEC, Sylvain has control over a total of 118,657 common shares of the company, with 118,657 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1093557/000109355725000249/xslF345X05/wk-form4_1757016814.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved